Article
Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia.
Movement disorders : official journal of the Movement Disorder Society - 1 Oct 2024
Sosero Yuri L, Bandres-Ciga Sara, Ferwerda Bart, Tocino Maria T P, Belloso Dìaz R, Gómez-Garre Pilar, Faouzi Johann, Taba Pille, Pavelka Lukas, Marques Tainà M, Gomes Clarissa P C, Kolodkin Alexey, May Patrick, Milanowski Lukasz M, Wszolek Zbigniew K, Uitti Ryan J, Heutink Peter, van Hilten Jacobus J, Simon David K, Eberly Shirley, Alvarez Ignacio, Krohn Lynne, Yu Eric, Freeman Kathryn, Rudakou Uladzislau, Ruskey Jennifer A, Asayesh Farnaz, Menéndez-Gonzàlez Manuel, Pastor Pau, Ross Owen A, Krüger Rejko, Corvol Jean-Christophe, Koks Sulev, Mir Pablo, De Bie Rob M A, Iwaki Hirotaka, Gan-Or Ziv
Abstract excerpt
BACKGROUND: Levodopa-induced dyskinesia (LID) is a common adverse effect of levodopa, one of the main therapeutics used to treat the motor symptoms of Parkinson's disease (PD). Previous evidence suggests a connection between LID and a disruption of the dopaminergic system as well as genes implicated in PD, including GBA1 and LRRK2. OBJECTIVES: Our goal was to investigate the effects of genetic variants on risk...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
